tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Replimune downgraded to Underweight from Neutral at JPMorgan

JPMorgan downgraded Replimune (REPL) to Underweight from Neutral without a price target The regulatory path forward for RP1 is unclear and potentially challenging, the analyst tells investors in a research note. The firm believes accelerated approval is less likely following the company’s Type A meeting with the FDA earlier this week. JPMorgan now sees potential for Replimune shares to underperform the broader biotech markets.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1